These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22166848)

  • 1. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
    Ismail-Beigi F; Craven TE; O'Connor PJ; Karl D; Calles-Escandon J; Hramiak I; Genuth S; Cushman WC; Gerstein HC; Probstfield JL; Katz L; Schubart U;
    Kidney Int; 2012 Mar; 81(6):586-94. PubMed ID: 22166848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
    Mottl AK; Buse JB; Ismail-Beigi F; Sigal RJ; Pedley CF; Papademetriou V; Simmons DL; Katz L; Mychaleckyj JC; Craven TE
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1693-1702. PubMed ID: 30361335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvascular benefits of hypertension and glucose control in type 2 diabetes.
    van Rensburg BW
    Cardiovasc J Afr; 2008; 19(4):179-80. PubMed ID: 18776957
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
    Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
    Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous Effects of Intensive Glycemic and Blood Pressure on Cardiovascular Events Among Diabetes by Living Arrangements.
    Kiyohara K; Kondo N; Iwami T; Yano Y; Nishiyama A; Node K; Inagaki N; Duru OK; Inoue K
    J Am Heart Assoc; 2024 Jul; 13(13):e033860. PubMed ID: 38934867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
    Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
    Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
    Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
    Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of medical therapies on retinopathy progression in type 2 diabetes.
    ; ; Chew EY; Ambrosius WT; Davis MD; Danis RP; Gangaputra S; Greven CM; Hubbard L; Esser BA; Lovato JF; Perdue LH; Goff DC; Cushman WC; Ginsberg HN; Elam MB; Genuth S; Gerstein HC; Schubart U; Fine LJ
    N Engl J Med; 2010 Jul; 363(3):233-44. PubMed ID: 20587587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annual deterioration of renal function in hypertensive patients with and without diabetes.
    Polonia J; Azevedo A; Monte M; Silva JA; Bertoquini S
    Vasc Health Risk Manag; 2017; 13():231-237. PubMed ID: 28721063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment.
    Zhou J; Xu B; He F; Shu Y; Chen X; Liu Z; Sun B; Zhang W
    Cardiovasc Diabetol; 2024 May; 23(1):166. PubMed ID: 38730425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
    Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of glycemia and blood pressure in British adults with diabetes mellitus and subsequent therapy choices: a comparison across health states.
    McAlister FA; Lethebe BC; Lambe C; Williamson T; Lowerison M
    Cardiovasc Diabetol; 2018 Feb; 17(1):27. PubMed ID: 29433515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
    Weber MA; Mansfield TA; Alessi F; Iqbal N; Parikh S; Ptaszynska A
    Blood Press; 2016; 25(2):93-103. PubMed ID: 26623980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa study.
    Yamada T; Komatsu M; Komiya I; Miyahara Y; Shima Y; Matsuzaki M; Ishikawa Y; Mita R; Fujiwara M; Furusato N; Nishi K; Aizawa T
    Diabetes Care; 2005 Nov; 28(11):2733-8. PubMed ID: 16249548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic control predicts diabetic extrarenal microvascular complications but not renal survival in patients with moderate to severe chronic kidney disease.
    Crook ED; Patel S
    Ethn Dis; 2006; 16(4):865-71. PubMed ID: 17061739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
    Cardoso CRL; Leite NC; Moram CBM; Salles GF
    Cardiovasc Diabetol; 2018 Feb; 17(1):33. PubMed ID: 29477146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.